Zimmer Biomet stock price ZBH share today Chart

Hanson has over 30 years of experience in the medical device industry and has held various executive positions in leading medical device companies. Additionally, Zimmer Biomet’s executive team includes Chief Financial Officer Suketu Upadhyay and Chief Operating Officer Ivan Tornos. Zimmer Biomet Holdings Inc is a medical technology company that designs, develops and manufactures a wide range of orthopedic and musculoskeletal products. With headquarters in Warsaw, Indiana, the company was formed in 2015 after the merger of Zimmer Holdings and Biomet Inc, two of the world’s leading companies in the orthopedic industry. Zimmer Biomet’s mission is to help people alleviate pain, regain mobility and improve the quality of life for patients worldwide.

Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return.

Securities products offered by Open to the Public Investing are not FDIC insured. Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits. JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries. The company’s leadership team is led by President and CEO Bryan Hanson, who has been in his current role since 2017.

The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. As of June 15th, there was short interest totaling 3,810,000 shares, an increase of 27.0% from the May 31st total of 3,000,000 shares.

Zimmer Biomet to Present at the 34th Annual Piper Sandler Healthcare Conference

Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered.

• The orthopedic industry is highly competitive, with a few major players dominating the market.
• Zimmer Biomet’s mission is to help people alleviate pain, regain mobility and improve the quality of life for patients worldwide.
• That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
• 240 employees have rated Zimmer Biomet Chief Executive Officer Bryan Hanson on Glassdoor.com.
• ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

Its S.E.T. product category includes sports medicine, biologics, foot and others. Alternative Assets.Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC. “Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of 1933 (as amended) (“Regulation A”). These investments https://g-markets.net/helpful-articles/how-to-interpret-the-macd-on-a-trading-chart/ are speculative, involve substantial risks (including illiquidity and loss of principal), and are not FDIC or SIPC insured. Alternative Assets purchased on the Public platform are not held in an Open to the Public Investing brokerage account and are self-custodied by the purchaser. The issuers of these securities may be an affiliate of Public, and Public (or an affiliate) may earn fees when you purchase or sell Alternative Assets.

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.17% per year. These returns cover a period from January 1, 1988 through May 15, 2023.

About Zimmer Biomet Hlds (ZBH)

Provides a general description of the business conducted by this company.

You can find your newly purchased ZBH stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.

The company has a robust pipeline of new products in development, including the Persona Revision Knee System and the ROSA Knee System. Zimmer Biomet is also pursuing strategic acquisitions to expand its presence in emerging markets and strengthen its position in existing markets. Third quarter net sales from continuing operations of $1.670 billion decreased 0.9% and increased 5.0% on a constant currency1 basis Third quarter diluted earnings per share from continuing operations… First quarter net sales of $1.831 billion increased 10.1% and 13.2% on a constant currency1 basis First quarter diluted earnings per share were $1.11; adjusted1 diluted earnings per share were $1.89 C… Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day.

It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Banking services and bank accounts are offered by Jiko Bank, a division of Mid-Central National Bank, Member FDIC. One share of ZBH stock can currently be purchased for approximately $142.37. Fourth quarter net sales from continuing operations of $1.825 billion increased 2.7% and 8.3% on a constant currency1 basis Fourth quarter diluted loss per share from continuing operations was $0.62; … The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Company Summary

A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZBH, but not buy additional shares or sell existing shares. The orthopedic industry is highly competitive, with a few major players dominating the market. Zimmer Biomet is one of the largest companies in the industry, with a strong presence in the joint reconstruction, spine, dental, and sports medicine markets. The industry is also highly regulated, with various regulatory bodies overseeing the safety and efficacy of medical devices. Zimmer Biomet has a track record of complying with regulatory requirements and maintaining high-quality standards.

• Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account.
• Zimmer Biomet has a track record of complying with regulatory requirements and maintaining high-quality standards.
• There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score.
• Zimmer Biomet is one of the largest companies in the industry, with a strong presence in the joint reconstruction, spine, dental, and sports medicine markets.

The company issued revenue guidance of $7.29 billion-$7.36 billion, compared to the consensus revenue estimate of $7.14 billion. Zimmer Biomet’s stock performance has been mixed over the past few years. In early 2020, the company’s stock price experienced a sharp decline due to the COVID-19 pandemic, but since then, it has rebounded and continues to experience volatility. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. The technique has proven to be very useful for finding positive surprises.

Zacks Research is Reported On:

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank.

For more information on risks and conflicts of interest, see these disclosures. No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC. An indication of interest to purchase securities involves no obligation or commitment of any kind.

Zimmer Biomet Holdings Inc. stock rises Thursday, still underperforms market

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

Based on an average daily trading volume, of 1,410,000 shares, the days-to-cover ratio is currently 2.7 days. One of the most significant risks facing Zimmer Biomet is the potential for regulatory changes that could impact the industry. Changes in regulatory requirements could increase the costs and time required to bring new products to market, affecting Zimmer Biomet’s ability to innovate and compete.

Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business. Amid recessionary concerns, investing in medical stock Abbott Laboratories (ABT) could be wise given its sound financials and the… Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. 240 employees have rated Zimmer Biomet Chief Executive Officer Bryan Hanson on Glassdoor.com. Bryan Hanson has an approval rating of 87% among the company’s employees. 66.0% of employees surveyed would recommend working at Zimmer Biomet to a friend. Sign-up to receive the latest news and ratings for Zimmer Biomet and its competitors with MarketBeat’s FREE daily newsletter.